Sorbent Therapeutics Appoints Jason Levin Chief Business Officer

       Sorbent Therapeutics Appoints Jason Levin Chief Business Officer

PR Newswire

SUNNYVALE, Calif., Dec. 5, 2012

SUNNYVALE, Calif., Dec. 5, 2012 /PRNewswire/ --Sorbent Therapeutics, Inc., a
biopharmaceutical company developing therapies for cardiovascular and renal
diseases, today announced that Jason Levin has joined the company as Chief
Business Officer.

Mr. Levin brings more than 18 years of industry experience to Sorbent.In this
newly created role, he will oversee Sorbent's business development efforts and
contribute to corporate strategy.Mr. Levin will report directly to Detlef
Albrecht, M.D., Sorbent's President and CEO.

"Jason brings significant business development and corporate strategy
expertise to our leadership team, and we have already benefitted from his
business acumen in his role as an advisor to Sorbent for the past several
months," said Dr. Albrecht."Sorbent's lead product for heart failure,
CLP1001, has achieved promising clinical results and our polymer technology
platform allows us to create first-in-class therapeutics addressing
significant unmet needs in heart failure, chronic kidney disease and
hypertension. Jason's contributions to building alliances and forming
partnerships will accelerate the development and commercialization of our
pipeline programs."

"With positive Phase 2a data for CLP1001, a solid management team and
compelling partnering opportunities, this is an exciting time to join
Sorbent. CLP1001 has demonstrated measurable clinical improvements in the
quality of life for heart failure patients by reducing fluid overload," said
Jason Levin. "Sorbent is well positioned for a variety of strategic
collaborations as we commence our planned Phase 2b study for CLP1001, and
evaluate opportunities to leverage the company's technology platform to
generate non-absorbed polymer-based therapeutics that restore fluid and ion
balances."

Jason Levin
Mr. Levin has been responsible for the completion of significant strategic
transactions across several companies generating more than $500 million in
value. Before joining Sorbent, Mr. Levin was responsible for in-licensing,
out-licensing and partnering as Chief Business Officer at BrainCells Inc. a
drug discovery and development company in San Diego, CA. Prior, he was Vice
President Corporate Development at Jazz Pharmaceuticals, a specialty
pharmaceutical company, where he was responsible for licensing, acquisitions,
corporate strategy and strategic alliances. Before joining Jazz
Pharmaceuticals, Mr. Levin was director of business development at ALZA
Corporation, a wholly owned subsidiary of Johnson & Johnson, where he was
responsible for both in- and out-licensing of the company's drug delivery
technology. Mr. Levin received an M.B.A. from the University of Texas, McCombs
Graduate School of Business, and a Bachelor's Degree from the University of
California at San Diego. He has been a member of the Licensing Executive
Society since 2000.

About Sorbent
Sorbent Therapeutics is a private biopharmaceutical company developing
therapies for patients requiring targeted cation and fluid removal from the
body. The company is focused on the development of non-absorbed polymeric
drugs to satisfy unmet clinical needs in large cardiovascular and renal
markets such as heart failure, end-stage renal disease, chronic kidney disease
and hypertension. Sorbent is headquartered in Sunnyvale, California. For
more information, visit www.sorbent.com.

SOURCE Sorbent Therapeutics, Inc.

Website: http://www.sorbent.com
Contact: Detlef F. Albrecht, M.D., President and CEO, +1-408-738-8240,
info@sorbent.com, BCC Partners, LLC, Karen L. Bergman or Michelle Corral,
+1-650-575-1509, +1-415-794-8662, kbergman@bccpartners.com,
mcorral@bccpartners.com
 
Press spacebar to pause and continue. Press esc to stop.